Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Weight loss through lifestyle changes is recommended for nonalcoholic fatty liver disease (NAFLD). However, its efficacy in patients with type 2 diabetes is unproven. RESEARCH DESIGN AND METHODS: Look AHEAD (Action for Health in Diabetes) is a 16-center clinical trial with 5,145 overweight or obese adults with type 2 diabetes, who were randomly assigned to an intensive lifestyle intervention (ILI) to induce a minimum weight loss of 7% or a control group who received diabetes support and education (DSE). In the Fatty Liver Ancillary Study, 96 participants completed proton magnetic resonance spectroscopy to quantify hepatic steatosis and tests to exclude other causes of liver disease at baseline and 12 months. We defined steatosis >5.5% as NAFLD. RESULTS: Participants were 49% women and 68% white. The mean age was 61 years, mean BMI was 35 kg/m2, mean steatosis was 8.0%, and mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 20.5 and 24.2 units/l, respectively. After 12 months, participants assigned to ILI (n = 46) lost more weight (−8.5 vs. −0.05%; P < 0.01) than those assigned to DSE and had a greater decline in steatosis (−50.8 vs. −22.8%; P = 0.04) and in A1C (−0.7 vs. −0.2%; P = 0.04). There were no significant 12-month changes in AST or ALT levels. At 12 months, 26% of DSE participants and 3% (1 of 31) of ILI participants without NAFLD at baseline developed NAFLD (P < 0.05). CONCLUSIONS: A 12-month intensive lifestyle intervention in patients with type 2 diabetes reduces steatosis and incident NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, histological improvement of different MASLD components depended on the amount of weight loss: Whereas about 5-7 % of weight loss already lead to a reduction in liver lipid content in 65 % of people with MASLD, MASH resolution (defined as the absence of hepatocellular ballooning) was achieved in 64 % by a 7-10 % decrease in body weight [46][47][48][49].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a 12‐month lifestyle intervention program in patients with type 2 diabetes, hepatic steatosis and incident NAFLD was significantly reduced [28].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Obesity, diabetes, and insulin resistance are the main risk factors for more advanced forms of the disease; up to 70–80% of individuals with NAFLD have insulin resistance or metabolic syndrome (3).”
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for Underlying Disease
Caldwell, S. H., Oelsner, D. H., Iezzoni, J. C., Hespenheide, E. E., Battle, E. H., & Driscoll, C. J. (1999) · Hepatology · doi:10.1002/hep.510290347 · Cited by 1,143
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Cited by
Items 201–300 of 366
Isoura, Y., Cho, Y., Fujimoto, H., Hamazaki, T., & Tokuhara, D. (2020) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2020.08.005 · Cited by 17
The Role of Diet in Non-alcoholic Fatty Liver Disease
Jun, D. W. (2013) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2013.61.5.243 · Cited by 15
Ketogenic Diet in Steatotic Liver Disease: A Metabolic Approach to Hepatic Health
Emanuele, F., Biondo, M., Tomasello, L., Arnaldi, G., & Guarnotta, V. (2025) · Nutrients · doi:10.3390/nu17071269 · Cited by 19
“The primary approach to managing MASLD remains as weight reduction through lifestyle modifications, including increased physical activity and caloric restriction [14,15].”
Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD
Hardy, T., & McPherson, S. (2017) · Current Hepatology Reports · doi:10.1007/s11901-017-0368-4 · Cited by 16
Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults
Lee, I., Cho, J., Park, J., & Kang, H. (2018) · Physical Activity and Nutrition · doi:10.20463/jenb.2018.0031 · Cited by 17
Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases
Spagnuolo, R., Montalcini, T., Bonis, D. D., Ferro, Y., Cosco, C., Mazza, E., Romeo, S., Doldo, P., & Pujia, A. (2019) · Nutrients · doi:10.3390/nu11020303 · Cited by 17
“However, the majority of studies have focused on the benefits of weight loss on hepatic steatosis and non-alcoholic steatotic hepatitis [32,33].”
BackgroundIncreasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors
Brunner, K. T., Pedley, A., Massaro, J. M., Hoffmann, U., Benjamin, E. J., & Long, M. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.003 · Cited by 15
Therapeutic approaches for non-alcoholic steatohepatitis
Gaal, L. F. V., Mertens, J., Francque, S., & Block, C. E. M. D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211034300 · Cited by 16
S2k-Leitlinie Klinische Ernährung in der Hepatologie
Plauth, M., Bechmann, L. P., Grajecki, D., Gundling, F., Kramer, L., Kremer, A. E., Rau, M., Schneider, A., Tacke, F., & van Thiel, I. (2024) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2338-1144 · Cited by 14
Behari, J., Graham, L., Wang, R., Schirda, C., Borhani, A. A., Methé, B. A., Li, K. W., Morris, A., Luu, H. N., Palmieri, S., et al. (2020) · Obesity Science & Practice · doi:10.1002/osp4.476 · Cited by 16
“Twelve months of intensive lifestyle intervention in patients with type 2 diabetes mellitus (DM) and 6 weeks of very low‐calorie diet in subjects with obesity was shown to reduce magnetic resonance spectroscopy‐determined hepatic fat.(3,4) Sustained weight loss through weight loss surgery leads to improvement in NAFLD…”
BackgroundA Comprehensive Review on Non-Alcoholic Fatty Liver Disease
Sahu, P., Chhabra, P., & Mehendale, A. M. (2023) · Cureus · doi:10.7759/cureus.50159 · Cited by 32
“Hepatic steatosis and the incidence of NAFLD were dramatically decreased in individuals with diabetes mellitus type 2 who participated in a 12-month lifestyle modification program [42].”
BackgroundNonalcoholic Fatty Liver Disease - The Clinician’s Perspective
Agrawal, S., & Duseja, A. (2014) · Tropical Gastroenterology · doi:10.7869/tg.219 · Cited by 17
Klein, S., & Romijn, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00036-8 · Cited by 16
Wang, X., Ma, B., Chen, J., You, H., Sheng, C., Yang, P., & Qu, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6620289 · Cited by 16
Semaglutide for Weight Loss: Was It Worth the Weight?
Novograd, J., Mullally, J., & Frishman, W. H. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000430 · Cited by 15
Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Tsoulfas, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3842 · Cited by 16
Rachakonda, V. P., DeLany, J. P., Kershaw, E. E., & Behari, J. (2019) · Hepatology Communications · doi:10.1002/hep4.1414 · Cited by 15
Obesity and Nonalcoholic Fatty Liver Disease
Chaney, A. J. (2021) · Nursing Clinics of North America · doi:10.1016/j.cnur.2021.07.009 · Cited by 16
Arora, C., Malhotra, A., Ranjan, P., Singh, V., Singh, N., Shalimar, S., Dwivedi, S. N., & Vikram, N. K. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-022-01111-8 · Cited by 13
Salaheldin, M., Aly, H. I. S., Lau, L. H. S., Afify, S., & El‐Kassas, M. (2023) · Diagnostics · doi:10.3390/diagnostics13162631 · Cited by 16
Schwartz, S. S., Fabricatore, A. N., & Diamond, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_31 · Cited by 17
Potential Approaches to Ameliorate Hepatic Fat Accumulation Seen with MTP Inhibition
Lin, M., Zhao, S., Shen, L., & Xu, D. (2014) · Drug Safety · doi:10.1007/s40264-014-0147-x · Cited by 14
Notch-ligand expression by NALT dendritic cells regulates mucosal Th1- and Th2-type responses
Fukuyama, Y., Tokuhara, D., Sekine, S., Kataoka, K., Markham, J. D., Irwin, A. R., Moon, G. H., Tokuhara, Y., Fujihashi, K., Davydova, J., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.12.046 · Cited by 13
“It was reported that microbial Ag-stimulated DCs regulate the differentiation of naïve CD4+ T cells into Th1 and Th2 lineages based upon their Notch-L expression [8-10, 12, 13].”
BackgroundCombined use of the CLivD score and FIB-4 for prediction of liver-related outcomes in the population
Åberg, F. O., Asteljoki, J. V., Männistö, V., & Luukkonen, P. K. (2023) · Hepatology · doi:10.1097/hep.0000000000000707 · Cited by 16
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Camacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 13
Medina, S. P., Kim, R. G., Magee, C., Stapper, N., & Khalili, M. (2023) · Obesity Science & Practice · doi:10.1002/osp4.688 · Cited by 12
“22,23 Similarly, alcohol cessation has been associated with improvements in FLD, though challenges exist in the sustainability of these habits in the long term.”
BackgroundDietary Manipulations for Nonalcoholic Fatty Liver Disease (NAFLD)
Cheah, M. C. C., McCullough, A. J., & Goh, G. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813822-9.00005-9 · Cited by 17
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Monserrat-Mesquida, M., Quetglas‐Llabrés, M. M., Bouzas, C., Montemayor, S., Mascaró, C. M., Casares, M., Llompart, I., Gámez, J. M., Tejada, S., Martínez, J. A., et al. (2022) · Antioxidants · doi:10.3390/antiox11071266 · Cited by 13
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 16
Dapagliflozin-Induced Acute-on-Chronic Liver Injury
Levine, J. A., Lo, A. A., Wallia, A., Rogers, M. C., & VanWagner, L. B. (2016) · ACG Case Reports Journal · doi:10.14309/crj.2016.142 · Cited by 11
Can follow‐up phone calls improve patients self‐monitoring of blood glucose?
Brown-Deacon, C. C., Brown, T., Creech, C. J., McFarland, M. R., Nair, A., & Whitlow, K. (2016) · Journal of Clinical Nursing · doi:10.1111/jocn.13367 · Cited by 11
Prevention of type 2 diabetes: what is the right target population?
Williamson, D. A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1535896 · Cited by 13
Fardet, A., Martin, J.-F., & Chardigny, J. (2011) · Journal of Food Composition and Analysis · doi:10.1016/j.jfca.2011.03.013 · Cited by 11
Exercise for Hepatic Fat Accumulation in Type 2 Diabetic Subjects
Bacchi, E., & Moghetti, P. (2013) · International Journal of Endocrinology · doi:10.1155/2013/309191 · Cited by 11
Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis
Abeysekera, K. W. M., Orr, J. G., Gordon, F. H., Howe, L. D., Hamilton-Shield, J. P., Heron, J., & Hickman, M. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02401-y · Cited by 12
“It has been demonstrated that a weight reduction of 5–7% is associated with a reversal of NAFL and non-alcoholic steatohepatitis [37], and weight loss of ≥ 10% is associated with hepatic fibrosis reversal [38].”
BackgroundZhang, P.-P., Wang, Y., Shen, F., Xing, Y., Gu, J.-Y., Li, X., Han, J., Jin, S., Xu, M., Wang, H., et al. (2024) · Trials · doi:10.1186/s13063-024-08046-4 · Cited by 14
“%) can produce benefits on NAFLD-related phenotypes [35, 36].”
BackgroundSREBP-1 und Fettleber: Klinische Bedeutung für Diabetes, Adipositas, Dyslipidämie und Atherosklerose
Müller‐Wieland, D., Knebel, B., Haas, J., & Kotzka, J. (2012) · Herz · doi:10.1007/s00059-012-3608-y · Cited by 10
Mechanisms underpinning the effect of exercise on the non-alcoholic fatty liver disease
Bekheit, M., Kamera, B. S., Colacino, L., Dropmann, A., Delibegović, M., Almadhoob, F., Hanafy, N. A. N., Bermano, G., & Hammad, S. (2025) · EXCLI journal · doi:10.17179/excli2024-7718 · Cited by 19
Noronha, J. C., Kendall, C. W. C., & Sievenpiper, J. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.875535 · Cited by 9
“6 years (10), reduced odds of non-alcoholic fatty liver disease (NAFLD) after 12 months (11), and 5-fold greater remission of obstructive sleep apnea (12).”
BackgroundSanguankeo, A., Lazo, M., Upala, S., Brancati, F. L., Bonekamp, S., Pownall, H. J., Balasubramanyam, A., Clark, J. M., & Fatty Liver Subgroup of the Look AHEAD Research Group (2016) · Endocrine Research · doi:10.1080/07435800.2016.1194856 · Cited by 10
“Of these, 151 underwent proton magnetic resonance spectroscopy ((1)H MRS) at baseline, and 102 underwent a (1)H MRS at 12 months (19).”
MethodSelf-citationNunez, D. J., Alexander, M., Yerges‐Armstrong, L. M., Singh, G., Byttebier, G., Fabbrini, E., Waterworth, D. M., Meininger, G. E., Galwey, N. W., Wallentin, L. C., et al. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00051.2018 · Cited by 9
NAFLD and cardiovascular disease
Martins, E., & Oliveira, A. B. F. D. (2018) · Porto Biomedical Journal · doi:10.1016/j.pbj.0000000000000002 · Cited by 9
Zhang, H., Jia, M., Su, Y., & Zhu, W. (2021) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2021.108919 · Cited by 12
The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus
Ganda, O. P. (2010) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0095 · Cited by 9
Annuzzi, G., Rivellese, A. A., Bozzetto, L., & Riccardi, G. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.12.001 · Cited by 11
Diabetes in Native Populations and Underserved Communities in the USA
Joseph, J. J., & Golden, S. H. (2016) · Springer eBooks · doi:10.1007/978-3-319-41559-8_14 · Cited by 9
Mitochondrial targeted therapies in MAFLD
Lai, S., Tang, D., & Feng, J. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151498 · Cited by 11
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis
Vuille‐Lessard, É., Lange, N. F., Riebensahm, C., Dufour, J., & Berzigotti, A. (2021) · Current Hepatology Reports · doi:10.1007/s11901-021-00563-z · Cited by 9
Diet and Exercise in the Treatment of Fatty Liver
Magkos, F., Lavoie, J.-M., Kantartzis, K., & Gastaldelli, A. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2012/257671 · Cited by 7
Storck, L. J., Meffert, P. J., Rausch, J., Gärtner, S., Aghdassi, A. A., Kühn, J., Kraft, M., Pietzner, M., Lerch, M. M., & Steveling, A. (2021) · Obesity Facts · doi:10.1159/000511453 · Cited by 9
A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease
Peng, K., Wang, S., Gao, L., & You, H. (2021) · Medicine · doi:10.1097/md.0000000000026415 · Cited by 7
“To adjust various confounding factors, we performed multivariate logistic regression analysis to further explore risk factors predisposed to NAFLD.”
ResultInfluentialFardet, A., Martin, J., & Chardigny, J. (2011) · Food & Function · doi:10.1039/c1fo10041f · Cited by 7
Giacco, R., Vetrani, C., Griffo, E., & Rivellese, A. A. (2013) · Current Nutrition Reports · doi:10.1007/s13668-013-0063-1 · Cited by 7
Arora, C., Malhotra, A., Ranjan, P., Vikram, N. K., Shalimar, S., Singh, N., & Dwivedi, S. N. (2019) · Cureus · doi:10.7759/cureus.5999 · Cited by 8
“A fatty liver ancillary study was carried out at one of the 16 Look AHEAD clinical sites with 244 participants [11].”
BackgroundNonalcoholic fatty liver disease in patients with type 2 diabetes
Petunina, N. A., & Эдуардовна, Т. М. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-4-92-95 · Cited by 8
Bermont, A., Cohen, D. L., Richter, V., Hadar, R., Tam, J., Wandel, A., Brawer, S., Grundman, O., & Shirin, H. (2025) · PharmaNutrition · doi:10.1016/j.phanu.2025.100429 · Cited by 6
Khalafi, M., Fatolahi, S., Symonds, M. E., Rosenkranz, S. K., Dinizadeh, F., & Batrakoulis, A. (2025) · Obesity Reviews · doi:10.1111/obr.70052 · Cited by 13
Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
Lee, H. A., Lee, H. A., & Kim, H. Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79428-6 · Cited by 7
Gallego‐Durán, R., Ampuero, J., Funuyet, J., & Romero‐Gómez, M. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.06.005 · Cited by 15
Zhou, Z., Gao, N., Liu, J., Ma, X., Ge, Z., & Cheng, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70168 · Cited by 8
Diagnosis and Management of Fatty Liver
Tan, P. O., Mustaffa, N., Tan, S. S., & Lee, Y. Y. (2020) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2020.308 · Cited by 5
Hershman, M., Torbjornsen, K., Pang, D., Wyatt, B. E., Dieterich, D. T., Perumalswami, P., Branch, A. D., & Dinani, A. M. (2022) · Obesity Science & Practice · doi:10.1002/osp4.637 · Cited by 5
“Still, in this and other lifestyle intervention studies for NAFLD, less than 50% of patients achieved weight loss of at least 7%.(15,16) A recent study assigned 716 patients with NAFLD to either a structured program conducted in person (five weekly meetings, n = 438) or web‐based (n = 278) with the primary outcome of…”
BackgroundSex Differences in Exercise Performance and Exercise Training Among Persons with Type 2 Diabetes
Quartuccio, M., Yalamanchi, S., Golden, S. H., Regensteiner, J. G., & Kalyani, R. R. (2017) · Contemporary diabetes · doi:10.1007/978-3-319-61013-9_7 · Cited by 6
Liraglutide for patients with non-alcoholic steatohepatitis
Gaborit, B., Darmon, P., Ancel, P., & Dutour, A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30734-6 · Cited by 5
Gómez, E. V., Friedman, S. L., & Romero‐Gómez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.10.040 · Cited by 7
Nagra, M., Goldman, D., Belury, M. A., & Messina, M. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2657527 · Cited by 6
HIV-Associated NAFLD: Disease Burden and Management
Kaplan, A. J., & Price, J. C. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00501-0 · Cited by 5
Mohammed, E. D., Abdel‐Naim, A. B., Jin, K., Jiang, R., Wei, J., & Sun, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118615 · Cited by 4
Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease
Hartl, L., Elias, J., Prager, G., Reiberger, T., & Unger, L. W. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2281 · Cited by 4
Zhang, J., Li, M.-T., Lin, S., Cheng, Y., Fan, J., & Chen, Y. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00110 · Cited by 4
A Systematic Review of Korean Medicine for Non-Alcoholic Fatty Liver Disease
Lee, Y., Cho, N.-K., Choi, H.-S., Kim, S.-M., & Kim, K.-S. (2019) · The Journal of Internal Korean Medicine · doi:10.22246/jikm.2019.40.1.13 · Cited by 4
Jeyakumar, S., & Vajreswari, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814466-4.00030-6 · Cited by 4
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Check, J. H., Brasile, D., Jk, C., Amui, J., & Wilson, C. (2009) · PubMed · Cited by 3
The main approaches to dietary changes in non-alcoholic fatty liver disease
Drapkina, O. M., Шепель, Р. Н., Starodubova, A. V., & Evsutina, Y. V. (2018) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20182106178 · Cited by 5
Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease
Jukić, L. V., Grgurević, I., Mikolašević, I., Kanižaj, T. F., Milić, S., Mrzljak, A., Premužić, M., Hrstić, I., Knežević-Štromar, I., Ljubičić, N., et al. (2021) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.s1.03 · Cited by 4
Adherence to lifestyle modification in patients with nonalcoholic fatty liver disease
Andreev, K. A., Skirdenko, Y. P., Николаев, Н. А., Livzan, M. A., Горбенко, А. В., Fedorin, M. M., & Сергеевна, К. Т. (2022) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2021-4-112-122 · Cited by 6
Treatment of Morbid Obesity: Intensive Lifestyle Intervention vs. Bariatric Surgery
Papamargaritis, D. (2013) · Surgery Current Research · doi:10.4172/2161-1076.1000147 · Cited by 3
“After RYGB 41-57% of patients have remission of T2DM after 1 year [32,50,51].”
Management of Patients with Nonalcoholic Fatty Liver Disease with Lifestyle Modification
Lee, B. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.2.82 · Cited by 3
“여러 연구들을 통해 체중감량과 간 내 지방량의 감소가 밀접하게 관련되어 있는 것이 잘 알려져 있다[2-6].”
Obesity and the Pathogenesis of Nonalcoholic Fatty Liver Disease
Fabbrini, E., & Magkos, F. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1203-2_9 · Cited by 5
Seip, R. L. (2012) · CRC Press eBooks · doi:10.1201/b12085-20 · Cited by 3
Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Bril, F., Ntim, K., Lomonaco, R., & Cusi, K. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch20 · Cited by 4
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2
Yang, L., Peng, T., Yan, X., & Lin, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-97140-x · Cited by 2
Cho, S. H., Kim, G., Lee, K., Oh, R., Kim, J. Y., Jang, M., Lee, Y., Jin, S., Hur, K. Y., Han, K., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0641 · Cited by 5
“The Look Action for Health in Diabetes (Look AHEAD) study found that the implementation of lifestyle changes resulted in an average weight reduction of 8%, which correlated with a significant decrease in liver fat [34].”
Xu, L., Hu, S., Ye, Y., Xie, X., Zhou, P., Shen, H., & Zhao, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-24948-7 · Cited by 1
“Intensive lifestyle interventions have shown promise in reducing weight, hepatic steatosis, and NAFLD in patients with type 2 diabetes [19].”
Diaz, D. J., Vattikuti, R. D., Janak, A., Yekula, A., Farooq, P. D., Ullah, A., Kothari, T. H., Kothari, S., Kaul, V., & Twohig, P. A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.111074 · Cited by 4
Delahanty, L. M., Fu, Y., & Thaweethai, T. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156325 · Cited by 2
KAHL, S., Caussy, C., & Cusi, K. J. (2026) · Diabetologia · doi:10.1007/s00125-026-06817-z · Cited by 2
Consensus Interdisciplinary Positions of the Metabolic Syndrome Supervisory Committee
Shlyakhto, E. V., Arutyunov, G. P., Babenko, A. Y., Boytsov, S. A., Вадимовна, В. С., Dedov, I. I., Drapkina, O. M., Олеговна, Е. С., Звартау, Н. Э., Ivashkin, V. T., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2026-7130 · Cited by 4
Non-alcoholic Fatty Liver Disease in Obesity
Ferolla, S. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19821-7_13 · Cited by 2
Utilization of antiobesity medications within the Military Health System
Neuman, T. J., Corrado, R., Banaag, A. L., & Koehlmoos, T. P. (2024) · Obesity · doi:10.1002/oby.24097 · Cited by 2
Kim, N. H. (2013) · Journal of Korean Biological Nursing Science · doi:10.7586/jkbns.2013.15.2.43 · Cited by 2
“TNF-α는 인슐린 신호전달과정을 저해하는데 핵심적인 역할을 하 며 그 외 염증성 경로를 활성화시키고 세포자멸사 과정도 촉진하 는 것으로 알려져 있다(Lazo et al., 2010).”
InfluentialTraitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques
Vergès, B. L. (2017) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(17)30166-9 · Cited by 2
Modifications decrease hepatic steatosis in Taiwanese with metabolic‐associated fatty liver disease
Liu, T., Qiu, H., Liu, S., Chien, C., Wang, J., Wong, M., Yi, C., Lin, L., Lei, W., Liang, S., et al. (2022) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12580 · Cited by 2
“, a healthy diet and habitual physical activity) has been shown to effectively reduce obesity-related liver steatosis and inflammation in patients with NASH in randomized controlled trials.(5,14,15) In general, 7%–10% weight loss in overweight and obese patients with fatty liver disease results in improvement of liver…”
BackgroundFranz, A. A., Shay, H., Kirpich, I., & McClain, C. J. (2025) · Seminars in Liver Disease · doi:10.1055/a-2725-5313 · Cited by 1
Metadata
- Authors
- Lazo, M., Solga, S. F., Horska, A., Bonekamp, S., Diehl, A. M., Brancati, F. L., Wagenknecht, L. E., Pi-Sunyer, F. X., Kahn, S. E., Clark, J. M., & for the Fatty Liver Subgroup of the Look AHEAD Research Group
- Affiliations
- Johns Hopkins University (US)
- Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland;
- Duke Medical Center (US)
- Wake Forest University Health Sciences (US)
- Division of Endocrinology, Diabetes and Nutrition, St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York;
- University of Washington (US)
- Corresponding author
- Lazo, Mariana
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-07-27
- Volume
- 33
- Issue
- 10
- Pages
- 2156-2163
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2945152
- OpenAlex
- W2086657936
- Cited by
- 367
- References
- 24
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 17 · 2023: 18 · 2022: 26 · 2021: 27 · 2020: 31 · 2019: 24 · 2018: 15 · 2017: 17 · 2016: 35 · 2015: 23 · 2014: 26 · 2013: 29 · 2012: 22
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Johns Hopkins University (M01-RR-00052)
- National Institutes of Health (RR-00052)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK57149, U01DK57149, U01DK057149, P30DK079637, R01DK060427)
- National Center for Research Resources (M01 RR-00052, M01RR000052)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 2 diabetes, non-alcoholic fatty liver disease, hepatic steatosis, intensive lifestyle intervention, weight loss, Look AHEAD trial, 1H NMR, diabetes support and education, glycemic control
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Fatty Liver, Female, Humans, Life Style, Male, Middle Aged, Weight Loss, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
